Copper Cu 64-Dota-Trastuzumab
Metastatic Malignant Neoplasm In The Brain
City of Hope Medical CenterUNKNOWNPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
100 Active assets in the Metastatic Malignant Neoplasm In The Brain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Trastuzumab Iambic Therapeutics, Inc | Phase 4 | BB |
Icotinib Betta Pharmaceuticals Co., Ltd. | Phase 3 | BB |
Trastuzumab Deruxtecan Baptist Health South Florida | Phase 4 | BB |
Capecitabine Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 3 | BB |
Regorafenib Neonc Technologies, Inc. | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Copper Cu 64-Dota-Trastuzumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →